SPAC Presentation

Procaps' Transaction Process Use of Proceeds $151 mm 1 Cash to Balance Sheet 1 2 $120 mm Inorganic Growth $31 mm Organic Growth H I ■ ■ ■ ■ ■ Roll-up strategy of mid-sized companies in the region Pharma targets in Mexico, CenAm and the Andean Region CDMO targets in Mexico and Brazil Key Development Areas - Telehealth and digital health Ophthalmic products and other select therapeutic areas Novel and orphan drug portfolios PROCAPS Capex Capacity expansion for new lyophilization production lines - Implement plant improvements - Variety of smaller projects to improve automatization processes Working capital investment improving liquidity position to obtain better trade terms Investments to strengthen e-Health platform R&D investments for new product developments / delivery technologies Over 600 new product launches in the next 3 years Source: Procaps Note: (1) $236mm in source funding ($200mm from UAC II minus $64 mm in redemptions plus $100mm from the PIPE), no warrant redemption, $60mm in secondary sale. Actual results in connection with the business combination may differ GROUP * 5

View entire presentation